Search





Search





Markets
/
Stocks
/
nasdaq-alks
/

Alkermes Plc

ALKS

Add to Watchlist

55.080USD

0.0000.00%

Close 06/26, 16:00（ET）Quotes delayed by 15 min

9.09BMarket Cap

59.24P/E TTM

Alkermes Plc

55.080

0.0000.00%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey 图表

Intraday

30m

Today

0.00%

5 Days

+22.43%

1 Month

+47.47%

6 Months

+93.33%

Year to Date

+96.85%

1 Year

+91.05%

Key Figures

--Open

0.000High

0.00Volume

59.24P/E TTM

125.08P/E Dynamic

--Dividend TTM

4.58%Turnover Ratio

55.080Prev. Close

0.000Low

0.00Turnover

24.77P/E Static

5.25P/B

0.00%Div Yield TTM

4.82%ROA

40.79052wk High

1.85Volume Ratio

367.07MNet Profit

165.10MShares

0.9298EPS TTM

0.31Beta

9.36%ROE

25.16552wk Low

5.47%Amplitude

81.36%Gross Margin

9.09BMarket Cap

14.40Reward/Risk

2.24%Risk Rate

TradingKey Stock Score of Alkermes Plc

Currency: USD Updated: 2026-06-26

Key Insights

Alkermes Plc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 3 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 48.12.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alkermes Plc's Score

Industry at a Glance

Industry Ranking

3 / 387

Overall Ranking

36 / 4566

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Alkermes Plc Highlights

StrengthsRisks

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Overvalued

The company’s latest PE is 59.24, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 182.39M shares, decreasing 6.17% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.